INDICATIONS RITUXAN HYCELA™ (rituximab/hyaluronidase human) is indicated for the treatment of adult patients with: ê Relapsed or refractory, follicular lymphoma (FL) as a single agent ê Previously untreated follicular lymphoma in combination with first-line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as singleagent maintenance therapy ê Non-progressing (including stable disease) follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy ê Previously untreated diffuse large B-cell lymphoma (DLBCL) in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens ê Previously untreated and previously treated chronic lymphocytic leukemia (CLL) in combination with fludarabine and cyclophosphamide (FC) Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of RITUXAN® RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions Please see the following pages for additional Important Safety Information and the brief summary of the full Prescribing Information, including BOXED WARNINGS. RSC-091217-0069_R01_RISC_JournalAd_King.indd 1-2